Basilea Pharmaceutica is focused on treating infectious diseases; marketed products are Cresemba (antifungal) and Zevtera (anti-MRSA broad-spectrum antibiotic). In late 2023, it expanded its pipeline to include BAL2062 (antifungal), tonabacase (antibiotic) and Phase III-ready fosmanogepix (antifungal).
There is an ever-increasing need for therapeutic agents that are efficacious against drug-resistant strains of bacteria (eg MRSA) or fungi. Hence the opportunities for Zevtera and Cresemba could be significant.
Healthcare |
Flash note
Healthcare |
Update
Healthcare |
Flash note
Healthcare |
edison tv
Adesh Kaul
CFO
David Veitch
CEO
Dung Tran
Investor relations coordinator
Forecast net debt (CHFm)
N/A
Forecast gearing ratio (%)
N/A
% | 1M | 3M | 12M |
---|---|---|---|
Actual | 19.9 | 26.7 | (4.7) |
Relative | 24.1 | 26.2 | (3.6) |
52 week high/low | CHF48.6/CHF32.2 |
In the lead up to its capital markets day, Basilea Pharmaceutica announced it has received initial funding of up to US$0.9m through a grant from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership backed by governments and foundations, for its preclinical antibiotics program. CARB-X is focused on supporting early-stage antibacterial research and development, and this grant is expected to support development work up until clinical candidate nomination in H224, with potential additional funding subject to achieving certain milestones. 2024 is shaping up to be an active year for Basilea, following the recent FDA approval and anticipated subsequent commercial launch of Zevtera in the US, as well as the initiation of Phase III studies for newly acquired antifungal asset Fosmanogepix (mid-2024).
Y/E Dec | Revenue (CHFm) | EBITDA (CHFm) | PBT (CHFm) | EPS (CHFc) | P/E (x) | P/CF (x) |
---|---|---|---|---|---|---|
2022A | 147.8 | 19.6 | 12.3 | 104.10 | 40.3 | N/A |
2023A | 157.6 | 20.8 | 10.8 | 89.66 | 46.8 | N/A |
2024E | 187.2 | 34.0 | 28.0 | 233.65 | 18.0 | N/A |
2025E | 209.1 | 37.9 | 32.3 | 269.24 | 15.6 | N/A |